Literature DB >> 17164666

Effects of a novel tripeptide on neurological outcomes after spinal cord injury.

Sunil M John1, Feng Bao, Yuhua Chen, Ronald D Mathison, Lynne C Weaver.   

Abstract

A biologically active tripeptide [phenylalanine glutamate glycine (feG)] derived from the submandibular gland has anti-inflammatory actions. We have shown that intravenous treatment with feG after spinal cord injury decreases the intraspinal infiltration of leukocytes and associated oxidative damage within 72 h after injury. The present study assessed effects of this treatment on chronic neurological outcomes after clip-compression spinal cord injury at the 12th thoracic segment. Locomotor scores of feG-treated rats were significantly higher than those of controls at 7 weeks after spinal cord injury. Treated rats had significantly less hind paw mechanical allodynia than controls at this time. In conclusion, the anti-inflammatory and anti-oxidative actions of feG treatment correlate with improved neurological outcomes after spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17164666     DOI: 10.1097/01.wnr.0000239963.83566.bb

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

1.  Validity of acute and chronic tactile sensory testing after spinal cord injury in rats.

Authors:  Megan Ryan Detloff; Leslie M Clark; Karen J Hutchinson; Anne D Kloos; Lesley C Fisher; D Michele Basso
Journal:  Exp Neurol       Date:  2010-07-17       Impact factor: 5.330

2.  Calcium-binding protein, spermatid-specific 1 is expressed in human salivary glands and contains an anti-inflammatory motif.

Authors:  Chris D St Laurent; Katherine E St Laurent; Ron D Mathison; A Dean Befus
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-01-28       Impact factor: 3.619

3.  Salivary gland derived peptides as a new class of anti-inflammatory agents: review of preclinical pharmacology of C-terminal peptides of SMR1 protein.

Authors:  Ronald D Mathison; Joseph S Davison; A Dean Befus; Daniel A Gingerich
Journal:  J Inflamm (Lond)       Date:  2010-09-28       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.